Religion & Medicine
In the study, the researchers monitored 1,802 patients at six hospitals who received coronary bypass surgery, in which doctors reroute circulation around a clogged vein or artery.Did it work? Well, no. In fact. it may have hurt a little bit.
The patients were broken into three groups. Two were prayed for; the third was not. Half the patients who received the prayers were told that they were being prayed for; half were told that they might or might not receive prayers.
The researchers asked the members of three congregations — St. Paul's Monastery in St. Paul; the Community of Teresian Carmelites in Worcester, Mass.; and Silent Unity, a Missouri prayer ministry near Kansas City — to deliver the prayers, using the patients' first names and the first initials of their last names.
The congregations were told that they could pray in their own ways, but they were instructed to include the phrase, "for a successful surgery with a quick, healthy recovery and no complications."
Analyzing complications in the 30 days after the operations, the researchers found no differences between those patients who were prayed for and those who were not.On the other hand, your chances of having major complications were slightly reduced if you'd been prayed for.
In another of the study's findings, a significantly higher number of the patients who knew that they were being prayed for — 59 percent — suffered complications, compared with 51 percent of those who were uncertain. The authors left open the possibility that this was a chance finding. But they said that being aware of the strangers' prayers also may have caused some of the patients a kind of performance anxiety.
"It may have made them uncertain, wondering am I so sick they had to call in their prayer team?" Dr. Bethea said.
The study also found that more patients in the uninformed prayer group — 18 percent — suffered major complications, like heart attack or stroke, compared with 13 percent in the group that did not receive prayers. In their report, the researchers suggested that this finding might also be a result of chance.
Also in the Times today (Friday), a front page article on trachoma.
What's trachoma? It's caused by a tiny organism called Chlamydia trachomatis, and it effects the eyes. Repeated infections cause scar tissue to build up under the eyelid, and for the eyelashs to turn underneath -- scratching the cornea and eventually leading to blindness. It occurs in poor, underdeveloped countries, and is very often spread by flies. (No doubt you've seen the pictures of flies swarming about weak, starving children). The World Health Organization estimates that 70 million people are infected with it. Five million suffer from its late stages. And two million are blind because of it. The disease itself and the blindness caused by it are entirely and pretty cheaply prevented.
One of the organizations that has been doing more than its share to help is Pfizer Pharmaceuticals. As much maligned as drug companies are these days (and deservedly so, in many cases) Pfizer should be lauded for what they're doing here.
The use of Zithromax, an antibiotic manufactured by Pfizer, has proved a breakthrough. The most common alternative is a cheap, messy antibiotic ointment that has to be applied twice daily to the eyes for six weeks. Zithromax, in contrast, can be taken in a single dose — making compliance easier and distribution to millions simpler.Another organization that has been doing a lot to help is the Carter Center. Founded and headed by former President Jimmy Carter, the Carter Center is a "nonprofit public policy center founded to fight disease, hunger, poverty, conflict, and oppression around the world". It's one of the reasons that Carter was awarded the Nobel Peace Prize in 2002. (It's up to history to evaluate the relative merits of presidents, but nowhere in my crystal ball do I see George W. ever winning one.)
By 2008, Pfizer, the world's largest drug maker, will have donated 145 million doses for trachoma control. Its contribution is administered by the International Trachoma Initiative, a nonprofit group. The drug has been provided in 11 of the 55 countries where trachoma remains a problem.
But globally, the World Health Organization estimates that at least 350 million people need the antibiotics once a year for three years to bring infection rates under control.
That equals more than a billion doses of azithromycin, the generic name for Zithromax. Trachoma is so rampant here in Ethiopia that an estimated 60 million people, or 86 percent of the country's population, need the drug.
Pfizer has not officially announced any additional donations, but Dr. Joseph M. Feczko, a Pfizer vice president, says the company will provide whatever is needed. "There's no cap or limit on this," he said. "We're in it for the long haul."
The significance of this article for us, ComMedia students, is its location -- front page, above the fold, in the New York Times. Trachoma is an ongoing problem. Millions of people can be kept from going needlessly blind, if enough people choose to do something about it. And a front page article in the Times will remind people of the necessity to do just that.
Now I don't call that liberal or conservative, religious or scientific -- I call it humanitarian.